Table 1.
ID | Sex | Age | Epi duration | MTS | PET | Non TL EEG | IRSA | Non-lat or contra sz | Side | Postop (months) | Engel outcome | Time to sz | ASM reduction | 2nd surg |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
11 | F | 41 | 4 | No | Yes | Yes | No | No | R | 63 | I | NA | No | No |
22 | M | 56 | 55 | No | No | No | No | No | R | 44 | I | NA | No | No |
23 | F | 51 | 5 | No | Yes | No | No | No | R | 42 | I | NA | Yes | No |
26 | F | 22 | 5 | No | Yes | No | No | No | R | 37 | I | NA | Yes | No |
4 | F | 42 | 26 | Yes | Yes | Yes | No | No | L | 52 | I | NA* | No | Yes |
6 | M | 25 | 15 | Yes | Yes | No | No | No | R | 64 | I | NA | Yes | No |
9 | M | 42 | 41 | Yes | Yes | No | No | No | L | 28 | I | NA# | No | Yes |
10 | F | 46 | 30 | Yes | No | No | No | No | R | 66 | I | NA | No | No |
14 | F | 46 | 23 | Yes | Yes | Yes | No | No | L | 38 | I | NA@ | Yes | Yes |
18 | F | 32 | 27 | Yes | Yes | No | No | No | R | 49 | I | NA | Yes | No |
20 | F | 61 | 34 | Yes | Yes | Yes | No | No | L | 39 | I | NA∧ | No | Yes |
29 | M | 67 | 50 | Yes | Yes | No | No | No | L | 18 | I | NA | No | No |
31 | M | 69 | 3 | Yes | Yes | No | No | No | L | 12 | I | NA | No | No |
2 | F | 53 | 3 | No | NA | No | Yes | No | R | 78 | II | 17 | Yes | No |
15 | F | 58 | 11 | Yes | No | Yes | Yes | No | R | 59 | II | 10 | No | No |
17 | M | 32 | 23 | Yes | Yes | Yes | Yes | No | L | 50 | II | 24 | Yes | No |
3 | M | 65 | 57 | Yes | No | Yes | No | Yes | L | 74 | II | 18 | Yes | No |
19 | M | 32 | 22 | No | No | No | No | No | R | 48 | II | 18 | Yes | No |
25 | F | 46 | 45 | Yes | Yes | Yes | No | No | R | 39 | II | 12 | Yes | No |
21 | F | 50 | 43 | No | No | Yes | Yes | No | L | 45 | III | 2 | Yes | No |
12 | M | 29 | 25 | Yes | Yes | Yes | Yes | No | L | 51 | III | 2 | No | Yes |
13 | M | 32 | 11 | No | Yes | No | No | Yes | L | 60 | III | 1 | No | No |
24 | F | 60 | 13 | No | No | Yes | No | Yes | R | 42 | III | 3 | No | No |
5 | F | 36 | 7 | No | Yes | Yes | No | No | L | 66 | III | 1 | No | No |
8 | F | 50 | 6 | No | Yes | No | No | No | R | 69 | III | 1 | No | No |
30 | F | 21 | 6 | Yes | Yes | Yes | No | No | R | 14 | III | 8 | No | No |
16 | F | 41 | 33 | No | No | Yes | Yes | Yes | R | 41 | IV | 1 | No | Yes |
7 | M | 20 | 5 | No | No | Yes | Yes | Yes | R | 62 | IV | 3 | No | Yes |
28 | M | 63 | 1 | Yes | NA | No | Yes | No | R | 37 | IV | 1 | No | No |
1 | M | 20 | 17 | No | NA | Yes | No | Yes | L | 79 | IV | 1 | No | No |
For patients who had a second surgery, time to seizure and postoperative follow-up duration are measured from the time of the second surgery.
Epi duration, duration of the epilepsy; MTS, ipsilateral mesial temporal lobe sclerosis; PET, ipsilateral temporal hypometabolism on positron emission tomography; non-TL EEG, non-temporal lobe interictal EEG findings; IRSA, interictal regional slow activity; Non-lat or contra sz, non-lateralizing or contra-lateralizing seizure onset; side, side of surgery; Post-op, post-op follow-up months; time to sz, time from surgery to first postoperative seizure; ASM; anti-seizure medications; 2nd surg, second surgery.
Patient 4 had a seizure 11 months after the first ablation and was seizure free at 52 months after the second ablation.
Patient 9 had a seizure 36 months after the first ablation and was seizure free at 28 months after the second ablation.
Patient 14 had a seizure 7 months after the first ablation and was seizure free at 38 months after the second ablation.
Patient 20 had a seizure 1 month after the first ablation and was seizure free at 39 months after the second ablation.